Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery

Inclusion Criteria:

• Scheduled for elective primary total knee replacement surgery
• Legal minimum age requirement ( country-specific)
• Written informed consent has been obtained

Exclusion Criteria:

• Documented history or considered to be at increased risk of venous thromboembolism

• Subjects considered to be at increased risk of bleeding:

  • Known hemorrhagic disorder and/or coagulation disorder
  • Thrombocytopenia
  • Clinically important bleeding occurred within 3 months prior to the screening visit

• Acute bacterial endocarditis

• Severe hypertension

• Retinopathy

• Concomitant use of anticoagulants / antiplatelet agents (including homeopathic drugs) and/or anticipated postoperative need for other reasons than prevention of DVT during the study period.